Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research

NovartisThe Novartis 2010 Immunology Prizes were presented at the 16th International Congress of Immunology in Kobe, Japan. Since 1992, the Novartis Prizes for Immunology have been awarded every third year for outstanding contributions to basic and clinical immunology. The prizes recognize individual achievement and provide financial support for further research by the recipients. The prizes are a major feature of the triennial International Congress of Immunology.

Professor Michael Bevan, Howard Hughes Medical Institute, University of Washington, Seattle, US, was awarded the Basic Immunology Prize for his research on T-cell selection and regulation and memory formation of CD8+ cytotoxic T cells in response to pathogens. His observations have led to a better understanding of how effective memory responses of T-cells - key players in the immune response - are generated. Several strategies underlying immunotherapy and cancer vaccine development are based on Professor Bevan's research.

Professor Charles Dinarello, University of Colorado at Denver, US, and Professor Juerg Tschopp, University of Lausanne, Switzerland, shared the Clinical Immunology Prize for their contributions to the discovery and regulation of Interleukin-1 beta and its biological properties as well as the use of IL-1 beta antagonists for the successful treatment of certain inflammatory diseases such as periodic inflammatory syndromes and gout.

"We are pleased to honor these scientists for their outstanding achievements which have not only lead to a better understanding of the immune system, but also to the development of therapies for immunological diseases," said Professor Dhavalkumar Patel, Head of NIBR Europe and Global Head of the Autoimmunity, Transplantation and Inflammation Disease Area at the Novartis Institutes for BioMedical Research (NIBR). "The Novartis Immunology Prizes are an integral part of our commitment to and appreciation of scientific innovation."

The winners of this year's prizes were selected by an independent panel of immunology experts chaired by Sir Andrew McMichael of the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. The Novartis Prizes are each worth CHF 100 000, and may be shared between more than one individual.

About Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 102,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...